Format

Send to

Choose Destination
J Exp Med. 2019 Jun 7. pii: jem.20190301. doi: 10.1084/jem.20190301. [Epub ahead of print]

The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes.

Author information

1
Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK.
2
Ifakara Health Institute, Bagamoyo, Tanzania.
3
Department of Medicine, University of Cambridge, Cambridge, UK.
4
Division of Nephrology, Department of Medicine and Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, NY.
5
European Vaccine Initiative, Heidelberg, Germany.
6
Babraham Bioinformatics Facility, Babraham Institute, Cambridge, UK.
7
Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
8
Renal Department, Lister Hospital, Stevenage, UK.
9
Swiss Tropical and Public Health Institute, Basel, Switzerland.
10
University of Basel, Switzerland.
11
Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK michelle.linterman@babraham.ac.uk.
#
Contributed equally

Abstract

The generation of protective humoral immunity after vaccination relies on the productive interaction between antigen-specific B cells and T follicular helper (Tfh) cells. Despite the central role of Tfh cells in vaccine responses, there is currently no validated way to enhance their differentiation in humans. From paired human lymph node and blood samples, we identify a population of circulating Tfh cells that are transcriptionally and clonally similar to germinal center Tfh cells. In a clinical trial of vaccine formulations, circulating Tfh cells were expanded in Tanzanian volunteers when an experimental malaria vaccine was adjuvanted in GLA-SE but not when formulated in Alum. The GLA-SE-formulated peptide was associated with an increase in the extrafollicular antibody response, long-lived antibody production, and the emergence of public TCRβ clonotypes in circulating Tfh cells. We demonstrate that altering vaccine adjuvants is a rational approach for enhancing Tfh cells in humans, thereby supporting the long-lived humoral immunity that is required for effective vaccines.

PMID:
31175140
DOI:
10.1084/jem.20190301

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center